Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Will the Blood Clot Issue Hurt AstraZeneca's Vaccine in the Long Term?

TheMotleyFool

0 0

Will the Blood Clot Issue Hurt AstraZeneca's Vaccine in the Long Term?

AstraZeneca's (NASDAQ: AZN) coronavirus vaccine has struggled to gain traction after side effects were discovered. In this video from Motley Fool Live, recorded on April 12, Fool.com contributors Brian Orelli and Keith Speights discuss not only the prospects for the vaccine but also the overall prospects for the British pharmaceutical company, which is what investors should be focused on.

Source Fool.com

Like: 0

AZN

Share